NLRP3 and neoplasm: These molecules include MCC950, CY-09, OLT1177, Tranilast and Oridonin, which exhibit therapeutic potentials by directly targeting NLRP3.122 More studies needed to determine whether these drugs inhibit postoperative MDSCs and their clinical efficacies in tumor resection patients.